Proactive Investors - Run By Investors For Investors

AstraZeneca sees further encouraging effects from leukaemia treatment Calquence

Interim analysis of a phase III clinical trial has revealed that after 12 months, 88% of people saw no progression of the disease if they were given the drug
AstraZeneca intends to make regulatory submissions for the drug later this year

An AstraZeneca PLC (LON:AZN) drug being developed to treat chronic lymphocytic leukaemia has shown that it significantly prolongs the time patients can live without the disease progressing.

An interim analysis of a phase III clinical trial has revealed that after 12 months, 88% of people who have previously treated for chronic lymphocytic leukaemia saw no progression of the disease if they were being given Calquence, compared to 68% for those patients using the physician's choice of rituximab combined with idelalisib or bendamustine.

READ: AstraZeneca drug for chronic lymphocytic leukaemia successfully navigates phase III Elevate trial

After just over 16 months of the Ascend trial, Calquence has been found to reduce the risk of disease progression or death by 69%.

Chronic lymphocytic leukaemia is the most common type of leukaemia in adults, with an estimated 191,000 new cases globally.

This trial is the first randomised test directly comparing a single drug against standard chemo-immunotherapy or idelalisib and rituximab combinations, doctors conducting the trial said. 

“These data add to the growing body of evidence to support the profile of Calquence as a selective BTK inhibitor that offers a chemotherapy-free treatment option with a favourable safety profile in chronic lymphocytic leukaemia, a life-threatening disease,” said José Baselga, executive vice president of Astra’s oncology research and development arm.

He said the Ascend data would be combined with recent positive results from other trials to serve as the foundation for regulatory submissions later this year, Baselga said.

Broker Shore Capital said the detailed data was "very promising" and "very significant" for the group's haematology franchise, but a head-to-head trial versus market leader Imbruvica was "the more likely catalyst to drive consensus upgrades upon a successful result". 

AstraZeneca shares were down 0.3% to 6,198p on Moday morning.

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

man with erectile dysfunction
June 17 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use